DE60215626D1 - Antagonist für die multimerisierung von hiv-1 vif-protein - Google Patents

Antagonist für die multimerisierung von hiv-1 vif-protein

Info

Publication number
DE60215626D1
DE60215626D1 DE60215626T DE60215626T DE60215626D1 DE 60215626 D1 DE60215626 D1 DE 60215626D1 DE 60215626 T DE60215626 T DE 60215626T DE 60215626 T DE60215626 T DE 60215626T DE 60215626 D1 DE60215626 D1 DE 60215626D1
Authority
DE
Germany
Prior art keywords
vif
hiv
antagonist
multimerization
multimerizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215626T
Other languages
English (en)
Other versions
DE60215626T2 (de
Inventor
Hui Zhang
Roger Pomerantz
Bin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Application granted granted Critical
Publication of DE60215626D1 publication Critical patent/DE60215626D1/de
Publication of DE60215626T2 publication Critical patent/DE60215626T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60215626T 2001-04-06 2002-04-08 Antagonist für die multimerisierung von hiv-1 vif-protein Expired - Lifetime DE60215626T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28227001P 2001-04-06 2001-04-06
US282270P 2001-04-06
PCT/US2002/011218 WO2002081504A2 (en) 2001-04-06 2002-04-08 Multimerization of hiv-1 vif protein as a therapeutic target

Publications (2)

Publication Number Publication Date
DE60215626D1 true DE60215626D1 (de) 2006-12-07
DE60215626T2 DE60215626T2 (de) 2007-08-30

Family

ID=23080751

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215626T Expired - Lifetime DE60215626T2 (de) 2001-04-06 2002-04-08 Antagonist für die multimerisierung von hiv-1 vif-protein

Country Status (8)

Country Link
US (4) US6653443B2 (de)
EP (1) EP1373308B1 (de)
JP (1) JP4234999B2 (de)
AT (1) ATE343591T1 (de)
AU (1) AU2002307229B2 (de)
CA (1) CA2442909C (de)
DE (1) DE60215626T2 (de)
WO (1) WO2002081504A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7138496B2 (en) * 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
EP1392846B1 (de) * 2001-02-27 2008-06-11 University of Rochester VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODIFIKATION DER BEARBEITUNG VON APOLIPOPROTEIN B-mRNA
DE60215626T2 (de) 2001-04-06 2007-08-30 Thomas Jefferson University Antagonist für die multimerisierung von hiv-1 vif-protein
EP2093286B1 (de) 2001-10-01 2013-02-27 Dyax Corporation Mehrkettige eukaryotische Display-Vektoren und deren Verwendungen
US7635681B2 (en) 2002-01-09 2009-12-22 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20050123973A1 (en) * 2002-02-08 2005-06-09 Shaobing Hua Methods for generating monoclonal antibody against fusion protein containing peptide fragment derived from membrane protein
WO2004013160A2 (en) * 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
ATE388961T1 (de) * 2003-05-23 2008-03-15 Univ Oregon Health & Science Verfahren zur identifikation von inhibitoren
US20050014137A1 (en) * 2003-07-17 2005-01-20 Agouron Pharmaceuticals, Inc. Lentivirus assay system including Vif protein activity
US20050112555A1 (en) * 2003-09-03 2005-05-26 Smith Harold C. Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof
EP1687022A4 (de) * 2003-11-12 2008-02-13 Medical Res Council Renta: hiv-immunogen und seine anwendungen
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
EP1890718A4 (de) 2005-02-11 2009-07-22 Univ Rochester Verfahren und zusammensetzungen in zusammenhang mit erhöhter apobec-1-protein-expression
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
JP5519291B2 (ja) * 2006-12-06 2014-06-11 トーマス・ジェファーソン・ユニバーシティ Ｈｉｖ−１感染症のためのペプチド及び治療法
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
JP2016504268A (ja) * 2012-10-04 2016-02-12 オヤジェン インコーポレイテッドＯｙａＧｅｎ， Ｉｎｃ． Ｖｉｆの自己会合を撹乱する抗ｈｉｖ剤としての小分子及びその使用方法
WO2014210082A2 (en) * 2013-06-24 2014-12-31 Oyagen, Inc. Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA3047000A1 (en) 2017-01-04 2018-07-12 Oyagen, Inc. Compounds, compositions, and methods for treating human immunodeficiency virus
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (de) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion
WO1995005851A1 (en) 1993-08-20 1995-03-02 St. Luke's-Roosevelt Hospital Center HIV vif-RELATED COMPOSITIONS, AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF
EP0980388A1 (de) 1997-05-20 2000-02-23 YISSUM RESEARCH DEVELOPMENT COMPANY of the Hebrew University of Jerusalem Vif-derivate als inhibitoren der hiv-protease
EP0959136A1 (de) * 1998-05-20 1999-11-24 Introgene B.V. Bei einem transporter von kationischen Aminosaüren zielgerichtete Darreichung
DE60215626T2 (de) 2001-04-06 2007-08-30 Thomas Jefferson University Antagonist für die multimerisierung von hiv-1 vif-protein

Also Published As

Publication number Publication date
CA2442909C (en) 2011-11-29
US7226741B2 (en) 2007-06-05
US20040086512A1 (en) 2004-05-06
CA2442909A1 (en) 2002-10-17
ATE343591T1 (de) 2006-11-15
DE60215626T2 (de) 2007-08-30
US20030013844A1 (en) 2003-01-16
US20080167199A1 (en) 2008-07-10
US20040146522A1 (en) 2004-07-29
US6653443B2 (en) 2003-11-25
JP4234999B2 (ja) 2009-03-04
US7498138B2 (en) 2009-03-03
EP1373308B1 (de) 2006-10-25
AU2002307229B2 (en) 2007-05-24
WO2002081504A2 (en) 2002-10-17
WO2002081504A3 (en) 2003-04-10
EP1373308A2 (de) 2004-01-02
JP2005516885A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
DE60215626D1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
ES2505144T3 (es) Agentes de unión selectivos antagonistas de proteína de unión de osteoprotegerina
ATE480562T1 (de) Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
ATE544870T1 (de) Profilierung einer rezeptorfamilie
EA200901646A1 (ru) Ингибиторы рецепторных тирозинкиназ и их применение
ATE550354T1 (de) Humane ringspezifische bnp-antikörper
UA108860C2 (xx) Моноклональне антитіло
ATE454404T1 (de) Intrazelluläre antikörper
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
DK1864131T3 (da) Naturlig ligand af G protein koblet receptor RCC356 og anvendelser deraf
WO2005114219A3 (en) Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
NO20052553D0 (no) Cobalaminanalyse.
DE602004017884D1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
ATE514778T1 (de) G-protein-gekoppelte rezeptor-antagonisten
DE60331059D1 (de) Verbesserter rezeptornachweis
ATE331038T1 (de) Verbessertes verfahren für reverses n-hybrid- screening
ATE368750T1 (de) Screening-verfahren zum identifizieren von g- proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen
ATE447610T1 (de) Kristalliner vap-1 und verwendung
ATE426807T1 (de) Proteomanalyse verfahren zum drogen vergleich
NO20035771L (no) Assays for EPF-reseptorforbindelser samt terapeutiske sammensetninger
ATE430317T1 (de) Enzymatische messung von imatinib-mesylat
ATE446512T1 (de) Doppeltes hybridsystem auf der basis von gen- silencing durch transkriptionelle interferenz
ATE403738T1 (de) Verfahren zur identifizierung von agonisten oder antagonisten für den gpr45like/gpr63 rezeptor
DK1294924T3 (da) Kompetitivt assay til identificering af allosteriske inhibitorer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition